Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus.
Item Type:Journal Article
Citation:Misstear K, McNeela EA, Murphy AG, Geoghegan JA, O'Keeffe KM, Fox J, Chan K, Heuking S, Collin N, Foster TJ, McLoughlin RM, Lavelle EC, Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus., The Journal of infectious diseases, 209, 9, 2014, 1479-1484
J Infect Dis.-2014-Misstear-1479-84.pdf (Published (author's copy) - Peer Reviewed) 614.5Kb
Despite showing promise in preclinical models, anti–Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.
Type of material:Journal Article
Series/Report no:The Journal of infectious diseases
Availability:Full text available